RANI News and Press, Rani Therapeutics Holdings Inc. From 11/09/22

SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company wil...

- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis - - RT-102 Phase 1 repeat-dose topline data anticipate...

SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company wi...

Gainers: Terns Pharmaceuticals ( TERN ) +36% . Rani Therapeutics ( RANI ) +25% . AirSculpt Technologies ( AIRS ) +21% . Larimar Therapeutics ( LRMR ) +21% . Neptune Wellness ( NEPT ) +18% . Losers: PLx Pharma ( PLXP ...

Rani Therapeutics ( NASDAQ: RANI ) said it terminated a public offering of its common stock previously announced on Aug. 10. The company added that current market conditions were not conducive for an offering on terms that would be in the best interests of its stockhol...

SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has t...

Rani Therapeutics ( NASDAQ: RANI ) on Wednesday said its capsule RT-102 for the potential treatment of osteoporosis was generally well-tolerated in a phase 1 study. The single-ascending dose portion of the early-stage study, called Study Part 1, met all its main goals, RAN...

Rani Therapeutics press release ( NASDAQ: RANI ): Q2 GAAP EPS of -$0.31 beats by $0.06 . Cash and cash equivalents as of June 30, 2022 were $97.2M, compared to $117.5M for the year ended December 31, 2021. For further details see: Rani Therapeutics GAAP EPS o...

SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it intends to offer and sell shares of its Class ...

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations into mid-2024 - SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) --...